drugset / Trial / NCT06582966
Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya
Phase 4
Completed
60 enrolled
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID) · collab
NaSingle-groupOpen-labelPrevention
Summary
The first study of doxycycline postexposure prophylaxis for cisgender women did not reduce incident STIs likely due to low use of doxycycline. Researchers will conduct a pilot study of once-weekly doxyxycline to prevent bacterial STIs among Kenyan cisgender women using PrEP for HIV prevention.
Timeline
- Start
- 2024-08-13
- Primary completion
- 2025-05-27
- Completion
- 2025-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 200 mg | Oral |